Latest Research
12 Articles
Cracking the KRAS Code
Dr. Despina Siolas is focusing her research on new treatments for pancreatic cancer, particularly ones that go after KRAS mutations.
Final Results of the Daraxonrasib Trial Are Unprecedented
When Dr. Brian Wolpin read the final results from the phase III daraxonrasib trial, everyone was on their feet at the 2026 ASCO meeting.
Accessing Daraxonrasib: A Quick Primer
Daraxonrasib, the first KRAS drug for pancreatic cancer, is now available through an expanded access program, but your physician must apply for you.
2026 AACR Annual Meeting Gives Hope for the Future
Research highlights from the 2026 AACR Meeting featured advances in pancreatic cancer treatment, focusing on KRAS and vaccines,
Large Clinical Trial For Cachexia Treatment
Lead investigator Dr. Jeffrey Crawford reports on the positive results from a cachexia clinical trial of a new immunotherapy drug to treat the condition.
Certain Oral Microbes May Raise Pancreatic Cancer Risk
Dr. Jiyoung Ahn is leading research into how the oral microbiome is related to the risk of developing pancreatic cancer.
FDA Approves Tumor Treating Fields For Locally Advanced Disease
Dr. Vincent Picozzi explains how the recently approved tumor treating fields device is changing the game for pancreatic cancer patients.
An Update on Drugs for KRAS Mutations
Drugs for KRAS are the focus of a number of clinical trials, and Dr. Allyson Ocean comments on the status of this research.
Research Highlights from ASCO GI 2026
The latest research on drugs targeting KRAS and new immuotherapy combinations were among the highlights of ASCO GI 2026.
New Neoadjuvant Treatment in Trials
Dr. Brian Wolpin provides an analysis of the latest data on a new neoadjuvant treatment for tumors that can be removed.
Rewinding 2025: A Year in Pancreatic Cancer Research
We take a look back at the research developments in 2025: KRAS, earlier detection and screening, vaccines, and clinical trials.
A Pancreas-Specific Blood Test Reaches Key Validation Milestones
Dr. Bryson Katona explains the advances in the latest pancreas-specific early detection blood test, to identify cancer at stage I and II.